Abstract and Introduction
Introduction
Posaconazole provides a broad spectrum of antifungal activity, has a relatively mild adverse effect profile, and is available in both tablet and liquid dosage forms making it a useful option as both prophylaxis and treatment. The oral suspension was approved by the Food and Drug Administration in 2006 for prophylaxis of invasive Aspergillus and Candida infections in severely immunocompromised patients, such as those chemotherapy-induced neutropenia or hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD). It is also approved for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory to treatment with fluconazole or itraconazole.[1] In 2013, a delayed-release posaconazole tablet was introduced, and approval for both the tablet and oral suspension was extended to patients 13 to 17 years of age. An injection for IV administration was approved in 2014, but only for use in adults.
Pediatr Pharm. 2018;24(9) © 2018 University of Virginia
